Avalo Therapeutics Files 8-K on Director/Officer Changes
Ticker: AVTX · Form: 8-K · Filed: Mar 26, 2025 · CIK: 1534120
| Field | Detail |
|---|---|
| Company | Avalo Therapeutics, INC. (AVTX) |
| Form Type | 8-K |
| Filed Date | Mar 26, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing-update
Related Tickers: AVTX
TL;DR
Avalo Therapeutics (AVTX) filed an 8-K: board/officer changes & comp details.
AI Summary
On March 25, 2025, Avalo Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also includes information on other events and financial statements, with the company previously known as Cerecor Inc. before a name change on November 2, 2011.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance structure, which could influence its strategic direction and operational focus.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate governance and compensation information, not indicating immediate financial distress or significant operational changes.
Key Numbers
- 001-37590 — SEC File Number (Identifies the company's filing history with the SEC.)
- 45-0705648 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Avalo Therapeutics, Inc. (company) — Registrant
- Cerecor Inc. (company) — Former company name
- March 25, 2025 (date) — Date of earliest event reported
- November 2, 2011 (date) — Date of name change
FAQ
What specific changes were made to the board of directors or executive officers?
The filing indicates 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' as an item of disclosure, but the specific details of these changes are not provided in the excerpt.
What are the key details regarding the compensatory arrangements of certain officers?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item, but the specific details of these arrangements are not included in the provided text.
What is the significance of the 'Other Events' section in this filing?
The 'Other Events' section is a catch-all for material events that do not fit into other specific 8-K item categories, but the nature of these events is not detailed in the excerpt.
When did Avalo Therapeutics, Inc. change its name from Cerecor Inc.?
Avalo Therapeutics, Inc. changed its name from Cerecor Inc. on November 2, 2011.
What is Avalo Therapeutics' primary business classification?
Avalo Therapeutics, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS' with the Standard Industrial Classification code 2834.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 26, 2025 regarding Avalo Therapeutics, Inc. (AVTX).